177 related articles for article (PubMed ID: 12615866)
21. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint.
Wise R; Andrews JM; Ashby JP
J Antimicrob Chemother; 2001 Oct; 48(4):563-7. PubMed ID: 11581239
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
Jørgen B; Merckoll P; Melby KK
Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
[TBL] [Abstract][Full Text] [Related]
23. Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007).
Sader HS; Moet G; Jones RN
J Chemother; 2009 Nov; 21(5):500-6. PubMed ID: 19933040
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
Sader HS; Streit JM; Fritsche TR; Jones RN
Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
[TBL] [Abstract][Full Text] [Related]
26. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
Int J Antimicrob Agents; 2014 May; 43(5):465-9. PubMed ID: 24636430
[TBL] [Abstract][Full Text] [Related]
27. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
28. The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis.
Shariati A; Dadashi M; Chegini Z; van Belkum A; Mirzaii M; Khoramrooz SS; Darban-Sarokhalil D
Antimicrob Resist Infect Control; 2020 Apr; 9(1):56. PubMed ID: 32321574
[TBL] [Abstract][Full Text] [Related]
29. Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003.
Sader HS; Fritsche TR; Streit JM; Jones RN
J Chemother; 2005 Oct; 17(5):477-83. PubMed ID: 16323435
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
31. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility Profile of Staphylococcus epidermidis and Staphylococcus haemolyticus Isolated from Blood Cultures to Vancomycin and Novel Antimicrobial Drugs over a Period of 12 Years.
Pinheiro L; Brito CI; Pereira VC; Oliveira A; Bartolomeu AR; Camargo CH; Cunha ML
Microb Drug Resist; 2016 Jun; 22(4):283-93. PubMed ID: 26623676
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.
Speciale A; La Ferla K; Caccamo F; Nicoletti G
Int J Antimicrob Agents; 1999 Sep; 13(1):21-8. PubMed ID: 10563401
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents.
Mendes RE; Castanheira M; Farrell DJ; Flamm RK; Sader HS; Jones RN
J Glob Antimicrob Resist; 2017 Mar; 8():28-32. PubMed ID: 27939809
[TBL] [Abstract][Full Text] [Related]
35. [A study of in vitro activity of daptomycin against 2679 Gram-positive cocci].
Zhang FF; Zhao CJ; Wang ZW; Liu WY; Yan W; Peng QS; Jiang S; Guo Y; Liu JB; Chen HB; Li HN; Wang Q; Wang H
Zhonghua Nei Ke Za Zhi; 2013 Jun; 52(6):474-9. PubMed ID: 24059993
[TBL] [Abstract][Full Text] [Related]
36. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.
Klastersky J
Cancer Treat Rev; 2003 Oct; 29(5):431-40. PubMed ID: 12972361
[TBL] [Abstract][Full Text] [Related]
37. [In vitro activity of daptomycin and other antimicrobial agents against 499 strains of gram-positive cocci causing bloodstream infection].
Yang QW; Wang H; Sun HL; Xu YC; Xie XL; Chen MJ
Zhonghua Nei Ke Za Zhi; 2009 Mar; 48(3):220-4. PubMed ID: 19576091
[TBL] [Abstract][Full Text] [Related]
38. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.
Streit JM; Jones RN; Sader HS
J Antimicrob Chemother; 2004 Apr; 53(4):669-74. PubMed ID: 14985278
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria.
Piper KE; Steckelberg JM; Patel R
J Infect Chemother; 2005 Aug; 11(4):207-9. PubMed ID: 16133715
[TBL] [Abstract][Full Text] [Related]
40. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
Rubinstein E; Bompart F
J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
